print this page

Clinical Trials: Infection


A Multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium Difficile-associated diarrhea (CDAD) (IRB# 566849)

(Infection)
  • Principal Investor
    Patrick Lee, MD
  • Summary

    The purpose of this study is to see if an investigational medication, cadazolid, is safe and more effective than vancomycin for the treatment of clostridium difficile-associated diarrhea (C-Diff). Participants in this trial will take either cadazolid or vancomycin for 10 days.

  • More Information

    Eligibility:

    To participate in this trial you must be 18 years or older and have diagnosis of Clostridium Difficile with active diarrhea.

  • Study Site Location
    Baystate Medical Center
  • Contact
    Courtney Reyes, RN
    413.794.2412
    Email

A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (IRB# 589257)

(Infection, Surgery)
  • Principal Investor
    Patrick Lee, MD
  • Summary

    The purpose of this study is to see if one of two different dosing regimens for an antibiotic already being used in adults, Dalvavancin, is safe and more effective. This antibiotic is currently approved by the FDA for the treatment of acute bacterial skin and skin structure infections.


    Participation in this trial would require 2 visits for IV antibiotic infusion and 3 other follow up visits

  • More Information

    Eligibility:


    To participate in this study you must be 18-85 years old and have an acute skin and/or skin structure infection requiring intravenous antibiotics.

  • Study Site Location
    Baystate Medical Center
  • Contact
    Courtney Reyes, RN
    413.794.2412

A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 In Patients With Clostridium Difficile Associated Diarrhea (IRB# BH-12-161)

(Infection, Surgery)
  • Principal Investor
    Patrick Lee, MD
  • Summary

    The purpose of this research study is to look at the safety and effectiveness of the study drug or oral vancomycin against Clostridium difficile Associated Diarrhea (CDAD). 

  • More Information

    Eligibility:

    To participate in the study you must be age 18-89, have a positive C. difficile toxin test and have 3 unformed bowel movements.

  • Study Site Location
    Baystate Medical Center
  • Contact
    Barbara Burkott, RN, BSN, CCRP
    413.794.1305
    Email